The information provided is not intended to be inclusive of all relevant published clinical studies or
open clinical trials. Physicians should incorporate test results with all information available in diagnosing
and determining appropriate treatment options for their patients.
PRÉCIS Indications for Use and Limitations
Studies indicate PRÉCIS is useful in tumor specimens from patients diagnosed with non-small cell lung cancer,
colorectal cancer, breast cancer, gastric cancer, melanoma, and GIST. Results should be interpreted in
conjunction with other laboratory and clinical findings. Performance characteristics refer to the analytical
performance of the test. Polymorphisms or mutations at locations not tested (see Methods) that may be
associated with drug efficacy or patient outcome will not be detected. bioTheranostics’ policy is to provide
physicians with flexibility to choose appropriate tests and to assure that the convenience of ordering a multi-test
profile does not prevent physicians from making informed decisions regarding which tests are medically necessary.
Each of the tests offered in the bioTheranostics test profile portfolio may be ordered individually using the
bioTheranostics Test Requisition. This test was developed and performance characteristics have been determined by bioTheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is
used for clinical purposes. It should not be regarded as investigational or for research. How this information
is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the
Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high complexity clinical